HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Trial ID or NCT#
Status
Purpose
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.
Official Title
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Eligibility Criteria
- - Has a documented diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy, classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy or wild-type ATTR (wtATTR) amyloidosis with cardiomyopathy meeting pre-specified diagnostic criteria - Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF OR clinical evidence of HF
- - Has known primary amyloidosis or leptomeningeal amyloidosis - Has New York Heart Association (NYHA) Class IV heart failure - Has NYHA Class III heart failure AND is at high risk based on pre-specified criteria - Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Screening visit - Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2 - Has received prior TTR-lowering treatment - Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to valvular heart disease, or cardiomyopathy due to ischemic heart disease
Investigator(s)
View on ClinicalTrials.gov